Assessment Status |
NCPE assessment ongoing |
HTA ID |
23048 |
Drug |
Fenfluramine (Fintepla®) |
Brand |
Fintepla® |
Indication |
Fenfluramine (Fintepla®) is indicated for seizures associated with Dravet Syndrome (as an add-on therapy for patients two years of age and older). |
Rapid review commissioned |
31/07/2023 |
Rapid review completed |
07/09/2023 |
Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of fenfluramine compared with the current standard of care. |
Full pharmacoeconomic assessment commissioned by HSE |
29/09/2023 |
Pre-submission consultation with Applicant |
07/11/2023 |
Full submission received from Applicant |
16/05/2024 |
Preliminary review sent to Applicant |
20/05/2024 |
NCPE assessment re-commenced |
17/06/2024 |